CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors

Part of paid clinical trials in Houston, Texas.

Sponsor
Baylor College of Medicine
Study ID
NCT07297160
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
0 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Dose Level -1 — BIOLOGICAL
    Dose Level -1: 3 x 10\^5 cells/kg
  • Dose Level 1 (starting dose level) — BIOLOGICAL
    Dose Level 1 (starting dose level): 1 x 10\^6 cells/kg
  • Dose Level 2 — BIOLOGICAL
    Dose Level 2: 3 x 10\^6 cells/kg
  • Dose Level 3 — BIOLOGICAL
    Dose Level 3: 1 x 10\^7 cells/kg

Study Details

This study is for patients who have a type of cancer that expresses the protein CD70, which includes lymphoma (lymph gland cancer), myeloma and solid tumors including some sarcomas and kidney cancers, and the cancer has come back or has not gone away after standard of care treatment. As there are limited or no remaining standard treatments available to treat this cancer, patients are being asked to volunteer to be in a gene transfer research study using special immune cells to create a specialized immune cell that will recognize a protein called CD70 that is expressed on the outside surface of the tumor cells in the body. This research study combines different ways of fighting disease by using T cells and "arming" them to recognize a specific protein on cancer cells. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells including tumor cells. T cells by themselves have been used to treat patients with cancers and have shown promise, but have not been strong enough to cure most patients. The protein used in this study is called anti-CD70. It has been developed from human CD27 on normal T cells, since it is the natural binding partner that can connect with CD70. This anti-CD70 protein sticks to tumor cells when it binds to CD70. CD70 binders have been used to treat people with different types of cancers. For this study, anti-CD70 has been changed so that instead of floating free in the blood it is now joined to the T cells. When binder is joined to a T cell in this way it is called a chimeric receptor or "CAR T cell". The doctors then made another change to cause these T cells to kill any cell that has CD70. This causes the "CAR T cells" to kill blood cancer cells which are confirmed to have CD70. In the laboratory, investigators have found that T cells work better if there are proteins added that stimulate T cells. The anti-CD70 (CD27) protein is unique because it can bind to CD70 on tumor cells but also stimulates the T cells that express it. Adding the CD27 makes the cells grow better and may help them to last longer in the body, thus giving the cells a better chance of killing the tumor cells. These CD70 "CAR" T cells are investigational products not approved by the Food and Drug Administration. The purpose of this study is to find a dose of CAR T cells that is safe, to learn what the side effects are and to see whether this therapy might help people with lymphoma (lymph gland cancer), myeloma and certain solid tumors including some sarcomas and kidney cancers.

Key Dates

Start date
Jun 30, 2026
Status verified
Mar 2026
Primary completion
Dec 31, 2029
Completion
Dec 31, 2044

Study Design

Enrollment
88 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment Arm A - Lymphoma and Solid Tumors
    CD70.CAR: Three dose levels, and a possible dose level -1 in case of unexpected toxicity at dose level 1, will be evaluated for patients with lymphoma and solid tumors. Each patient will receive one T cell infusion. Dose levels will be defined based on number of transduced T cells measured by flow cytometry. The first three patients treated on the study will be adults 18 years of age or older, which can be treated in each cohort.
  • Experimental: Treatment Arm B - Myeloma
    CD70.CAR: Three dose levels, and a possible dose level -1 in case of unexpected toxicity at dose level 1, will be evaluated for patients with myeloma. Each patient will receive one T cell infusion. Dose levels will be defined based on number of transduced T cells measured by flow cytometry. The first three patients treated on the study will be adults 18 years of age or older, which can be treated in each cohort.

Primary Outcome Measure

Dose limiting toxicity (DLT) rate [ Time Frame: 4 weeks post infusion ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Texas Children's HospitalHoustonTexas77030
Bilal Omer, MD
[email protected]
832-826-0860
Brandon Garner
[email protected]
The Methodist HospitalHoustonTexas77030
Bilal Omer, MD
[email protected]
832-826-0860
Brandon Garner
[email protected]

Find similar trials in Houston, TX

By condition
Kidney cancerMultiple myeloma
By specialty
OncologyUrologyBlood cancer
By research site
Texas Children's Hospital· Houston, TXThe Methodist Hospital· Houston, TX

Related Studies